Barclays Initiates Coverage on Baxter International Inc to Overweight

Barclays Initiates Coverage on Baxter International Inc(NYSE:BAX). The shares have been rated Overweight. The rating by Barclays was issued on Sep 15, 2016.

In a different note, On Jul 28, 2016, UBS said it Maintains its rating on Baxter International Inc. In the research note, the firm Raises the price-target to $48.00 per share. The shares have been rated ‘Neutral’ by the firm. On Jul 27, 2016, JP Morgan said it Maintains its rating on Baxter International Inc. In the research note, the firm Raises the price-target to $45.00 per share. The shares have been rated ‘Neutral’ by the firm.

Baxter International Inc (BAX) made into the market gainers list on Tuesdays trading session with the shares advancing 0.30% or 0.14 points. Due to strong positive momentum, the stock ended at $47.39, which is also near the day’s high of $47.75. The stock began the session at $47.43 and the volume stood at 42,96,189 shares. The 52-week high of the shares is $49.485 and the 52 week low is $32.18. The company has a current market capitalization of $25,775 M and it has 54,38,87,680 shares in outstanding.

Baxter International Inc(BAX) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.58B. Analysts had an estimated revenue of $2.51B. Earnings per share were $0.46. Analysts had estimated an EPS of $0.39.

Several Insider Transactions has been reported to the SEC. On May 24, 2016, Jose E Almeida (CEO) purchased 11,691 shares at $42.75 per share price.Also, On May 4, 2016, John D Forsyth (director) sold 1,887 shares at $44.38 per share price.On Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price, according to the Form-4 filing with the securities and exchange commission.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.